Lisdexamfetamine, sold under the brand name Vyvanse among , is a medication that is used to treat attention deficit hyperactivity disorder (ADHD) in people over the age of five as well as for moderate to severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. In the United Kingdom it is usually less preferred than methylphenidate. Its effects generally begin within 2 hours and last for up to 12 hours.

Property Value
dbo:abstract
  • Lisdexamfetamine, sold under the brand name Vyvanse among , is a medication that is used to treat attention deficit hyperactivity disorder (ADHD) in people over the age of five as well as for moderate to severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. In the United Kingdom it is usually less preferred than methylphenidate. Its effects generally begin within 2 hours and last for up to 12 hours. Common side effects of lisdexamfetamine include loss of appetite, anxiety, diarrhea, trouble sleeping, irritability, and nausea. Rare but serious side effects include mania, sudden cardiac death in those with underlying heart problems, and psychosis. It has a high potential for abuse per the DEA. Serotonin syndrome may occur if used with certain other medications. Its use during pregnancy may result in harm to the baby and use during breastfeeding is not recommended by the manufacturer. Lisdexamfetamine is a central nervous system (CNS) stimulant that works after being converted by the body into dextroamphetamine. Chemically, lisdexamfetamine is composed of the amino acid L-lysine, attached to dextroamphetamine. Lisdexamfetamine was approved for medical use in the United States in 2007. A month supply in the United Kingdom costs the British National Health Service about ¬£58 as of 2019. In the United States, the wholesale cost of this amount is about US$264. In 2016, it was the 99th most prescribed medication in the United States, with more than 7 million prescriptions. It is a Schedule II controlled substance in the United Kingdom and a Schedule II controlled substance in the United States. (en)
dbo:alternativeName
  • Tyvense, Elvanse, Vyvanse, others (en)
dbo:bioavailability
  • 96.400002 (xsd:float)
dbo:casNumber
  • 608137-32-2
dbo:chEMBL
  • 1201222
dbo:drugbank
  • DB01255
dbo:fdaUniiCode
  • H645GUL8KJ
dbo:medlinePlus
  • a607047
dbo:pubchem
  • 11597698
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-07-15 03:47:12Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 9687089 (xsd:integer)
dbo:wikiPageLength
  • 27414 (xsd:integer)
dbo:wikiPageModified
  • 2019-07-15 03:47:02Z (xsd:date)
dbo:wikiPageOutDegree
  • 138 (xsd:integer)
dbo:wikiPageRevisionID
  • 906323283 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Lisdexamfetamine, sold under the brand name Vyvanse among , is a medication that is used to treat attention deficit hyperactivity disorder (ADHD) in people over the age of five as well as for moderate to severe binge eating disorder in adults. Lisdexamfetamine is taken by mouth. In the United Kingdom it is usually less preferred than methylphenidate. Its effects generally begin within 2 hours and last for up to 12 hours. (en)
rdfs:label
  • Lisdexamfetamine (en)
rdfs:seeAlso
owl:differentFrom
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is owl:differentFrom of
is foaf:primaryTopic of